Sanofi, Glax­o­SmithK­line jump back in­to the PhI­II race for a Covid vac­cine — as the win­ners con­gre­gate be­hind the fin­ish line

Sanofi got out ear­ly in the race to de­vel­op a vac­cine us­ing more of a tra­di­tion­al ap­proach, then de­railed late last year as their can­di­date failed to work in old­er peo­ple. Now, af­ter like­ly miss­ing the bus for the bulk of the world’s af­flu­ent na­tions, they’re back from that em­bar­rass­ing col­lapse with a sec­ond at­tempt us­ing GSK’s ad­ju­vant that may get them back on track — with a po­ten­tial Q4 launch that the rest of the world will be pay­ing close at­ten­tion to.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER